WebApr 13, 2024 · Om Stayble Therapeutics AB. Stayble är ett kliniskt läkemedelsbolag som utvecklar injektionsbehandlingen STA363 mot degenerativ disksjukdom (DDD) och kroniskt diskbråck (LDH). Staybles vision är att kunna erbjuda patienter en enkel och effektiv behandling som angriper den underliggande orsaken till patientens kroniska smärta och … WebMar 30, 2024 · Historical Prices for Stayble Therapeutics Registered Shs Feb. 28 2024 Mar. 30 2024 Download Reset Price change over selected period: -8.51% -0.01 Stayble Therapeutics Registered Shs Analyst...
Stayble Therapeutics CHRONIC LOW BACK PAIN, cLBP …
WebFeb 13, 2024 · Phone: +46 730 808 397 About Stayble Therapeutics AB Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. WebCurrently also CEO at Cereno Scientific AB and Chairman of the Board at Stayble Therapeutics AB and AcuCort AB. A seasoned professional with international experience in various sectors, including Pharmaceutical, Biotechnology, Finance, Renewable Energy, and Management Consulting. corporate event photography nyc
Stayble Therapeutics AB (publ) (STABL.ST) - Yahoo Finance
WebStayble Therapeutics AB - Company Profile and News - Bloomberg Markets Bloomberg Terminal Demo Request Bloomberg Connecting decision makers to a dynamic network of … WebStayble Therapeutics AB (”Stayble” or the ”Company”) is currently conducting a phase 2b study with the drug candidate STA363. The Company now presents positive interim data with established safety and tolerability as well as lower dispersion in pain measurements when analyzing now available blinded data from the six-month follow-up in ... WebFeb 24, 2024 · Stayble Therapeutics AB engages in the development of pharmaceutical products. It develops an injectable treatment against chronic low back pain triggered by disc degeneration. The company was ... farbe asphalt